Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dna X (SONM) Total Non-Current Liabilities (2018 - 2025)

Historic Total Non-Current Liabilities for Dna X (SONM) over the last 8 years, with Q3 2025 value amounting to $39.1 million.

  • Dna X's Total Non-Current Liabilities rose 2150.76% to $39.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $39.1 million, marking a year-over-year increase of 2150.76%. This contributed to the annual value of $43.7 million for FY2024, which is 3606.25% up from last year.
  • Per Dna X's latest filing, its Total Non-Current Liabilities stood at $39.1 million for Q3 2025, which was up 2150.76% from $35.7 million recorded in Q2 2025.
  • In the past 5 years, Dna X's Total Non-Current Liabilities registered a high of $43.7 million during Q4 2024, and its lowest value of $20.1 million during Q1 2021.
  • In the last 5 years, Dna X's Total Non-Current Liabilities had a median value of $29.7 million in 2023 and averaged $29.7 million.
  • In the last 5 years, Dna X's Total Non-Current Liabilities tumbled by 2932.71% in 2024 and then soared by 6802.38% in 2025.
  • Quarter analysis of 5 years shows Dna X's Total Non-Current Liabilities stood at $21.1 million in 2021, then soared by 53.02% to $32.2 million in 2022, then decreased by 0.2% to $32.1 million in 2023, then soared by 36.06% to $43.7 million in 2024, then fell by 10.59% to $39.1 million in 2025.
  • Its Total Non-Current Liabilities was $39.1 million in Q3 2025, compared to $35.7 million in Q2 2025 and $35.2 million in Q1 2025.